Skip to content

Scholar Rock SRRK Additional Paid-In Capital

Additional Paid-In Capital at other companies

Biogen logo
BiogenBIIB
$896.7M+42.4%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$2.78B+6.5%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$1.61B+5.8%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$1.83B+75.5%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$2.11B+9.0%
Arrowhead Research logo
Arrowhead ResearchARWR
$2.4B+13.7%

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%
Enterprise value$5.45B+82.6%
P/S170.9×

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's additional paid-in capital?
Scholar Rock (SRRK) reported additional paid-in capital of $1.68B in Q1 2026.
How has Scholar Rock's additional paid-in capital changed year-over-year?
Scholar Rock's additional paid-in capital increased by 28.4% year-over-year, from $1.31B to $1.68B.
What is the long-term trend for Scholar Rock's additional paid-in capital?
Over 5 years (2020 to 2025), Scholar Rock's additional paid-in capital has grown at a 25.1% compound annual growth rate (CAGR), from $505.07M to $1.55B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.